GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes
The evidence is consistent across all three: most people regain a significant portion of lost weight after discontinuation
Given that semaglutide and tirzepatide slow gastric emptying and therefore increase the time any oral substance spends in a stomach-acid environment, protective delivery technology is more relevant for GLP-1 users than for people with standard gastric transit
Other emergency contraception options, including ulipristal acetate (ella) and copper IUDs, are effective for up to 5 days after unprotected intercourse
Due to the concern about the growing prevalence of unapproved GLP-1s on the market, the FDA issued warning letters to the following companies in December: The FDA warned the companies about potential violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act), even with the companies claiming some of their GLP-1 products were currently for research purposes only
[2] SGLT2 inhibitors (such as dapagliflozin or empagliflozin) offer cardiovascular and renal benefits alongside glucose-lowering effects and typically produce modest weight loss through urinary glucose excretion